EVIDENCE Meta-Analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma

This meta-analysis was based on the FDA guidance for considerations for a meta-analysis of minimal residual disease (MRD) as a clinical endpoint and evaluates MRD-negativity as an early endpoint reasonably likely to predict long-term clinical benefit.